Deletion of 2‐aminoadipic semialdehyde synthase limits metabolite accumulation in cell and mouse models for glutaric aciduria type 1
- 21 June 2020
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 43 (6) , 1154-1164
Abstract
Glutaric aciduria type 1 (GA1) is an inborn error of lysine degradation characterized by acute encephalopathy that is caused by toxic accumulation of lysine degradation intermediates. We investigated the efficacy of substrate reduction through inhibition of 2‐aminoadipic semialdehyde synthase (AASS), an enzyme upstream of the defective glutaryl‐CoA dehydrogenase (GCDH), in a cell line and mouse model of GA1. We show that loss of AASS function in GCDH‐deficient HEK‐293 cells leads to an approximately fivefold reduction in the established GA1 clinical biomarker glutarylcarnitine. In the GA1 mouse model, deletion of Aass leads to a 4.3‐, 3.8‐, and 3.2‐fold decrease in the glutaric acid levels in urine, brain, and liver, respectively. Parallel decreases were observed in urine and brain 3‐hydroxyglutaric acid levels, and plasma, urine, and brain glutarylcarnitine levels. These in vivo data demonstrate that the saccharopine pathway is the main source of glutaric acid production in the brain and periphery of a mouse model for GA1, and support the notion that pharmacological inhibition of AASS may represent an attractive strategy to treat GA1.Keywords
This publication has 47 references indexed in Scilit:
- Genetic basis of hyperlysinemiaOrphanet Journal of Rare Diseases, 2013
- DHTKD1 Mutations Cause 2-Aminoadipic and 2-Oxoadipic AciduriaThe American Journal of Human Genetics, 2012
- Mechanism of age-dependent susceptibility and novel treatment strategy in glutaric acidemia type IJournal of Clinical Investigation, 2007
- Intracerebral accumulation of glutaric and 3‐hydroxyglutaric acids secondary to limited flux across the blood–brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl‐CoA dehydrogenase deficiencyJournal of Neurochemistry, 2006
- Neuropathological, biochemical and molecular findings in a glutaric acidemia type 1 cohortBrain, 2005
- Clinical Course, Early Diagnosis, Treatment, and Prevention of Disease in Glutaryl-CoA Dehydrogenase DeficiencyNeuropediatrics, 1996
- A G-to-T transversion at the +5 position of intron 1 in the glutaryl CoA dehydrogenase gene is associated with the island Lake variant of glutaric acidemia type IHuman Molecular Genetics, 1995
- Hyperlysinemia with saccharopinuria due to combined lysine-ketoglutarate reductase and saccharopine dehydrogenase deficiencies presenting as cystinuriaThe Journal of Pediatrics, 1979
- Treatment of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria)The Journal of Pediatrics, 1979
- Glutaric aciduria; A “new” disorder of amino acid metabolismBiochemical Medicine, 1975